Arthritis and pain - Future targets to control osteoarthritis pain

被引:98
作者
Dray, Andy
Read, Simon J.
机构
[1] AstraZeneca R&D, Montreal, PQ H4S 1Z9, Canada
[2] AstraZeneca R&D Mereside, Macclesfield SK10 4TG, Cheshire, England
关键词
D O I
10.1186/ar2178
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain therapy exemplified by molecular targets that alter sensitization and hyperexcitability of the nervous system, for example, opioids and cannabinoids. We highlight opportunities for targeting inflammatory mediators and their key receptors (for example, prostanoids, kinins, cytokines and chemokines), ion channels (for example, NaV1.8, NaV1.7 and CaV2.2) and neurotrophins (for example, nerve growth factor), noting evidence that relates to their participation in OA etiology and treatment. Future neurological treatments of pain appear optimistic but will require the systematic evaluation of emerging opportunities.
引用
收藏
页数:14
相关论文
共 175 条
[1]   Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain [J].
Ali, Z ;
Raja, SN ;
Wesselmann, U ;
Fuchs, PN ;
Meyer, RA ;
Campbell, JN .
PAIN, 2000, 88 (02) :161-168
[2]   NERVE GROWTH-FACTOR IN THE SYNOVIAL-FLUID OF PATIENTS WITH CHRONIC ARTHRITIS [J].
ALOE, L ;
TUVERI, MA ;
CARCASSI, U ;
LEVIMONTALCINI, R .
ARTHRITIS AND RHEUMATISM, 1992, 35 (03) :351-355
[3]   ORL1 receptor-mediated internalization of N-type calcium channels [J].
Altier, C ;
Khosravani, H ;
Evans, RM ;
Hameed, S ;
Peloquin, JB ;
Vartian, BA ;
Chen, L ;
Beedle, AM ;
Ferguson, SSG ;
Mezghrani, A ;
Dubel, SJ ;
Bourinet, E ;
McRory, JE ;
Zamponi, GW .
NATURE NEUROSCIENCE, 2006, 9 (01) :31-40
[4]   PERIPHERAL ADMINISTRATION OF NERVE GROWTH-FACTOR IN THE ADULT-RAT PRODUCES A THERMAL HYPERALGESIA THAT REQUIRES THE PRESENCE OF SYMPATHETIC POSTGANGLIONIC NEURONS [J].
ANDREEV, NY ;
DIMITRIEVA, N ;
KOLTZENBURG, M ;
MCMAHON, SB .
PAIN, 1995, 63 (01) :109-115
[5]  
[Anonymous], J PAIN
[6]  
Apfel SC, 2002, INT REV NEUROBIOL, V50, P393
[7]   Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity [J].
Apostolidis, A ;
Popat, R ;
Yiangou, Y ;
Cockayne, D ;
Ford, APDW ;
Davis, JB ;
Dasgupta, P ;
Fowler, CJ ;
Anand, P .
JOURNAL OF UROLOGY, 2005, 174 (03) :977-982
[8]   Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions [J].
Araujo, MC ;
Sinnott, CJ ;
Strichartz, GR .
PAIN, 2003, 103 (1-2) :21-29
[9]   Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin [J].
Bandell, M ;
Story, GM ;
Hwang, SW ;
Viswanath, V ;
Eid, SR ;
Petrus, MJ ;
Earley, TJ ;
Patapoutian, A .
NEURON, 2004, 41 (06) :849-857
[10]  
BANDWARD PA, 2000, J AUTONOM NERV SYST, V81, P146